3-(3-chloro-propyl)-3-methyl-1-phenyl-3,4-dihydro-1H-quinolin-2-one | 792122-67-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 3-(3-chloro-propyl)-3-methyl-1-phenyl-3,4-dihydro-1H-quinolin-2-one
• 英文别名: 3-(3-chloropropyl)-3-methyl-1-phenyl-4H-quinolin-2-one
• CAS: 792122-67-9
• 化学式: C₁₉H₂₀ClNO
• 分子量: 313.827
• InChiKey: NOCFGJSPFRSTQK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-[3-(甲基氨基)丙基]-1-苯基-3,4-二氢喹啉-2-酮 、 3-(3-chloro-propyl)-3-methyl-1-phenyl-3,4-dihydro-1H-quinolin-2-one 以to give the crude product (198 mg), which的产率得到3-methyl-3-(3-methylamino-propyl)-1-phenyl-3,4-dihydro-1H-quinolin-2-one
  参考文献：
  名称：

  Quinolone derivatives

  摘要：

  本发明涉及式（I）化合物，其中—X—，n，R1，R3和Ar—具有在此定义的值，它们的制备以及用作药物的用途。

  公开号：

  US20070105845A1
• 作为产物：
  描述：

  3,4-dihydro-3-methyl-1-phenylquinolin-2(1H)-one 、 3-(3-氯丙基)-1-苯基-3,4-二氢喹啉-2-酮 、 1-溴-3-氯丙烷 、 生成 3-(3-chloro-propyl)-3-methyl-1-phenyl-3,4-dihydro-1H-quinolin-2-one
  参考文献：
  名称：

  Quinolone derivatives

  摘要：

  本发明涉及式（I）化合物，其中—X—，n，R1，R3和Ar—具有在此定义的值，它们的制备以及用作药物的用途。

  公开号：

  US20070105845A1

文献信息

• 3,4-DIHYDRO-1H-QUINOLIN-2-ONE DERIVATIVES AS NOREPINEPHRINE REUPTAKE INHIBITORS
  申请人：ELI LILLY AND COMPANY

  公开号：EP1622874B1

  公开（公告）日：2007-10-03
• Treatment of pervasive developemental disorders with norepinephrine reuptake inhibitors
  申请人：Allen John Albert

  公开号：US20060241188A1

  公开（公告）日：2006-10-26

  Provided are methods and medicaments for treating a Pervasive Developmental Disorder, comprising administering to a patient in need of such treatment an effective amount of a selective norepinephrine reuptake inhibitor.
• Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition
  申请人：Allen John Albert

  公开号：US20070015786A1

  公开（公告）日：2007-01-18

  Selective norepinephrine reuptake inhibitors are useful for the prevention or treatment of hot flashes, vasomotor symptoms, impulse control disorders or personality change due to a general medical condition.
• Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors
  申请人：Kelsey Kenneth Douglas

  公开号：US20070032554A1

  公开（公告）日：2007-02-08

  Provided are methods and medicaments for treating stuttering or another communication disorder, comprising administering to a patient in need of such treatment an effective amount of a selective norepinephrine reuptake inhibitor.
• Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors
  申请人：Sumner Russell Calvin

  公开号：US20070105960A1

  公开（公告）日：2007-05-10

  Provided are methods and medicaments for treating a learning disability or a Motor Skills Disorder, comprising administering to a patient in need of such treatment an effective amount of a selective norepinephrine reuptake inhibitor.